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Mice transgenic with the human poliovirus receptor gene develop clinical signs and neuropathology similar to those of
human poliomyelitis when neurovirulent polioviruses are inoculated into the central nervous system (CNS). Factors contrib-
uting to disease severity and the frequencies of paralysis and mortality include the poliovirus strain, dose, and gender of the
mouse inoculated. The more neurovirulent the virus, as defined by monkey challenge results, the higher the rate of paralysis,
mortality, and severity of disease. Also, the time to disease onset is shorter for more neurovirulent viruses. Male mice are
more susceptible to polioviruses than females. TGM-PRG-3 mice have a 10-fold higher transgene copy number and produce
3-fold more receptor RNA and protein levels in the CNS than TGM-PRG-1 mice. CNS inoculations with type III polioviruses
differing in relative neurovirulence show that these mouse lines are similar in disease frequency and severity, demonstrating
that differences in receptor gene dosage and concomitant receptor abundance do not affect susceptibility to infection.
However, there is a difference in the rate of accumulation of clinical signs. The time to onset of disease is shorter for
TGM-PRG-3 than TGM-PRG-1 mice. Thus, receptor dosage affects the rate of appearance of poliomyelitis in these mice.
© 1999 Academic Press
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Poliovirus is a small positive-stranded RNA virus with
tropism for the human nervous system. When neuro-
nvasive, this picornavirus causes a central nervous sys-
em (CNS) disease known as poliomyelitis. Natural trans-
ission of poliovirus occurs via a fecal to oral route.
nce ingested, poliovirus replicates first in the orophar-
nx and then in the gastrointestinal tract prior to estab-
ishing viremia (Sabin, 1956). In a small percentage of
ases, poliovirus is transported to the CNS, either
hrough the blood–brain barrier (Koike et al., 1994; No-
oto et al., 1994; Yang et al., 1977) or an extraneural site
ridging the central and peripheral nervous systems
Bodian, 1955; Racaniello et al., 1993; Racaniello and
en, 1994; Ren and Racaniello, 1992). Replication of
oliovirus in neurons causes degeneration and/or neu-
onal loss resulting in lesions and accompanying dis-
ase symptoms. If poliovirus destroys the motor neurons
f the spinal cord, spinal poliomyelitis or leg muscle
aralysis results. If poliovirus destroys the neurons in the
edulla oblongata, bulbar poliomyelitis or paralysis of
espiratory muscles results. Depending on the extent of
NS damage, poliovirus infections may also result in
eath (Brownell and Tomlinson, 1984).
1 To whom correspondence and reprint requests should be addressed.
pax: (914) 732-4941. E-mail: anne_deatly@internetmail.pr.cyanamid.com.
221The natural host range of polioviruses is restricted to
umans due to expression of the poliovirus receptor (pvr).
he PVR, a single copy gene on human chromosome 19
Koike et al., 1990), is a member of the immunoglobulin
uperfamily (Mendelsohn et al., 1989). A homolog of this
ene is also encoded by nonhuman primates, causing
hem to be susceptible to poliovirus infection and disease
nly when virus is inoculated into the CNS (Koike et al.,
992). Mice transgenic with the PVR gene (TgPVR mice)
ay, therefore, be useful in exploring poliovirus replication
nd subsequent disease pathogenesis.
In this report, TGM-PRG-1 and TGM-PRG-3 (Deatly
t al., 1998) mice were inoculated in the spinal cord
ith modified live polioviruses to examine poliovirus
eurovirulence and poliomyelitis. This study focuses
n the observations of the clinical signs of poliomyeli-
is in infected mice (similar to those of human disease)
hich become paralyzed, die, or are unaffected. The
esults of six intraspinal (IS) challenge studies dem-
nstrated the following: a higher proportion of mice
ere affected and the clinical signs of poliomyelitis
ere more severe when they were inoculated with a
eurovirulent poliovirus (vaccine 3B) compared to an
ttenuated poliovirus reference strain (i.e., WHO/III,
sed as a passed vaccine control in the monkey neu-
ovirulence test); the proportion of mice affected and
isease severity increased with increasing dose of
oliovirus; and a higher proportion of male mice were
0042-6822/99 $30.00
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222 DEATLY ET AL.ffected than female mice when inoculated with vac-
ine 3B or the WHO/III reference virus.
By intracranial (IC) inoculation, the two TgPVR mouse
ines appear to have similar susceptibilities to wild-type III
oliovirus, even though their receptor expression levels
iffer by threefold (Deatly et al., 1998). The same two mouse
ines, TGM-PRG-1 and TGM-PRG-3, were also used in this
tudy, and the results obtained for each mouse line were
ompared to assess their relative susceptibilities to less
eurovirulent type III polioviruses administered IS. As in the
revious study, these two mouse lines were similar in their
usceptibility to poliovirus, even when less neurovirulent
irus strains were inoculated in the spinal cord. Therefore,
he dosage of the PVR gene and the difference in abun-
ance of the receptor in the brain (Deatly et al., 1998) do not
ffect the overall susceptibility of TgPVR mice to type III
olioviruses inoculated in the CNS tissues. However, re-
eptor gene dosage and abundance of pvr in CNS tissues
ffect the time to onset of disease. By statistical analysis,
he difference in failure time of these two mouse lines was
ignificant. The failure time of TGM-PRG-3 mice, the mouse
ine with a threefold higher level of pvr in the brain, is at
east 1 day shorter than that of TGM-PRG-1 mice. Because
n the majority of cases, clinical signs in mice develop from
ays 2 to 5, 1 day represents a 25% shorter failure time for
GM-PRG-3 mice relative to TGM-PRG-1 mice.
RESULTS
S inoculation of TGM-PRG-1 and TGM-PRG-3 mice
ith polioviruses
Factors affecting poliovirus neurovirulence. To inves-
T
Proportions of Transgeni
Line Vaccine Doseb
E
1 2 3
GM-PRG-1 3B 2 .000 .000 .10
3 .300 .400 .30
4 .700 .900 .50
5 .800 .800 1.00
WHO/III 2 .000 .000 .00
3 .000 .000 .00
4 .100 .500 .40
5 .500 .500 .60
GM-PRG-3 3B 2 .100 .000 .30
3 .500 .200 .30
4 .900 .300 .90
5 .800 .900 .80
WHO/III 2 .000 .000 .00
3 .100 .000 .10
4 .400 .400 .40
5 .400 .500 .90
a Clinical signs include paralysis and/or death.
b The doses are in log10 TCID50.igate how TGM-PRG-1 and TGM-PRG-3 mice respond ao different strains of type III poliovirus, mice from both
ransgenic lines were inoculated with either a neuro-
irulent type III poliovirus, vaccine 3B, or an attenuated
oliovirus type III reference strain, WHO/III. These
olioviruses differ in the percentage content of 472-C,
hich correlates with neurovirulence of type III polio-
iruses (Chumakov et al., 1991). We determined that
accine 3B contains 4.78% C and the WHO/III refer-
nce virus contains 0.44% C at position 472, which is
imilar to results reported by others (Dragunsky et al.,
996). Wild-type III poliovirus has approximately 100%
at position 472.
Groups of 10 mice from each line were inoculated with
ach of four doses (102, 103, 104, and 105 TCID50) by the
S route. The virus inoculum was delivered to the spinal
ord to target motor neurons enervating the hind limb
uscles. Following challenge, the mice were observed
or 14 days for the development of hind limb paralysis
nd/or death. Any mice without signs of poliomyelitis
ere designated “unaffected.” The parameters of neuro-
irulence expressed by TgPVR mice following virus chal-
enge, i.e. paralysis and mortality, are similar to clinical
igns of spinal poliomyelitis in humans.
Poliovirus strain. The proportions of TGM-PRG-1 and
GM-PRG-3 mice inoculated with vaccine 3B or WHO/III
eference virus showing clinical signs (paralysis or mor-
ality) for each of the six tests are illustrated in Table I.
ven though there is variability from test to test in the
roportions of mice affected at the respective doses, the
ean proportions demonstrate that higher numbers of
GM-PRG-1 and TGM-PRG-3 mice developed paralysis
Showing Clinical Signsa
ent
Mean SD Mean PD504 5 6
.000 .100 .000 .033 .052
.200 .600 .300 .350 .138 3.67 6 0.34
.400 .800 .700 .667 .186
.800 .800 .500 .783 .160
.000 .000 .000 .000 .000
.000 .100 .000 .017 .041 4.52 6 0.20
.500 .400 .200 .350 .164
.900 .700 .800 .667 .163
.100 .300 .100 .150 .122
.300 .500 .500 .383 .133 3.45 6 0.41
.600 .700 .700 .683 .223
.778 1.000 .700 .830 .105
.100 .000 .000 .017 .041
.100 .300 .000 .100 .110 4.45 6 0.27
.100 .400 .200 .317 .133
.800 .700 .800 .650 .187ABLE 1
c Mice
xperim
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223POLIOMYELITIS IN PV-SENSITIVE MICEhe WHO/III reference virus at comparable doses. In
ddition, clinical signs of poliomyelitis were more severe
n mice inoculated with vaccine 3B than the WHO/III
eference; i.e., a greater proportion of the mice that
eveloped clinical signs died.
Since the proportions of clinical signs were highly
imilar for the two mouse lines, data from both were
ompiled to determine the effects of virus strain on
esponse frequencies. Figure 1 displays logistic regres-
ion curves for paralysis of the 959 TGM-PRG-1 and
GM-PRG-3 mice inoculated IS with the type III poliovi-
us vaccines, WHO/III and vaccine 3B. To illustrate the
ifference in the probability of paralysis for each polio-
irus tested at log10 dose of 4.0 TCID50/mL, TgPVR mice
ave a 60–62% probability to be affected by vaccine 3B
nd a 28–30% probability to be affected by WHO/III. The
ose at which 50% of the mice were paralyzed (PD50) is
03.5 TCID50 for vaccine 3B and 10
4.6 TCID50 for the
HO/III reference virus. Therefore, significantly less vac-
ine 3B virus is needed to cause paralysis than is re-
uired for the reference virus. Also, both TGM-PRG-1 and
GM-PRG-3 mice are able to differentiate the neuroviru-
ent poliovirus from the reference strain on the basis of
linical signs.
Poliovirus dose. Table I also illustrates the dose-
ependent response of these poliovirus-sensitive
ice to each poliovirus. The higher the dose of virus
noculated, the greater the number of mice that devel-
ped clinical signs of poliomyelitis. The mean PD50
alues of all six experiments for each poliovirus and
ach mouse line were calculated (Table I). As illus-
rated, the six tests showed similar PD50 values for
ach virus in either mouse line. TGM-PRG-1 and TGM-
FIG. 1. Dose–response curves for TGM-PRG-1 and TGM-PRG-3
ouse lines. For TGM-PRG-1 mice (dotted lines) and TGM-PRG-3 mice
solid lines), the probability of paralysis calculated by logistic regres-
ion is plotted against vaccine dose per mouse (in log10 TCID50 units).
accine 3B is on the left and WHO/III is on the right. Data from male
nd female data mice are combined.RG-3 mice had 0.85 and 1.00 log lower PD50 values, cespectively, for the vaccine 3B than the WHO/III ref-
rence challenges.
omparing poliovirus susceptibility of TGM-PRG-1
nd TGM-PRG-3 mouse lines
Logistic regression was used to compare the relative
usceptibilities of TGM-PRG-1 and TGM-PRG-3 mice to
oliovirus infection. Figure 1 portrays the dose re-
ponses of TGM-PRG-1 and TGM-PRG-3 mice inoculated
ith vaccines 3B and WHO/III. As depicted, both mouse
ines showed similar response curves to each of the
iruses. Less than 0.3 log dose units separate TGM-
RG-1 and TGM-PRG-3 regression curves for vaccine 3B
t the 50% probability level, and the two lines are virtually
dentical for the WHO/III virus.
Contingency table analysis of the six tests combined
ound no significant differences between TGM-PRG-1
nd TGM-PRG-3 mice in paralysis and mortality rates (P
alues of .1432 and .2051, respectively). Taken together,
hese results demonstrate that TGM-PRG-1 and TGM-
RG-3 mice are very similar in their susceptibilities to
ype III polioviruses.
Failure time, the time from inoculation of the virus to
nset of disease signs, was compared by proportional
azards to evaluate potential differences in poliovirus
usceptibility of the two mouse lines. For these type III
iruses, the peak time for development of clinical signs is
rom day 2 to day 5 postinoculation. Failure times for
ines TGM-PRG-1 and TGM-PRG-3 are illustrated in the
urvival curves shown in Fig. 2. Clinical signs appeared
ore rapidly in TGM-PRG-3 mice. Adjusting for experi-
ent, dose, and sex in the regression, the P value for the
ifference between the two mouse lines was significant
P 5 .0384).
FIG. 2. Survival curves. Survival (no clinical signs of poliomyelitis-
naffected) is shown for TGM-PRG-1 mice (solid line) and TGM-PRG-3
ice (dotted line) over the course of 14 days following IS inoculation
ith vaccine 3B. Data from male and female mice at all doses areombined.
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224 DEATLY ET AL.ffect of gender on development of poliomyelitis in
gPVR mice
Figure 3 illustrates the differences in responses of
ale and female TGM-PRG-1 and TGM-PRG-3 mice to a
hallenge with vaccines 3B and WHO/III for all six tests.
he probability of paralysis for males and females from
oth mouse lines post-IS inoculation with the WHO/III
eference virus is plotted versus the dose (Fig. 3A). The
D50 values for females and males inoculated with the
HO/III reference virus were 4.93 and 4.10, respectively.
imilarly, there is a greater probability for males to de-
FIG. 3. Paralysis rates for male and female mice. Paralysis rates are
hown for male mice (hatched bars) and female mice (solid bars)
noculated IS with WHO/III reference virus (A) or vaccine 3B (B) from
ombined TGM-PRG-1 and TGM-PRG-3 data (total of 959 mice). Doses
re in log10 TCID50 units.elop clinical signs when inoculated with the vaccine 3B tt each dose (Fig. 3B). The PD50 values for females and
ales inoculated with the vaccine 3B virus were 4.30 and
.84, respectively. The ratio of males:females that devel-
ped paralysis differs with dose, with an overall ratio of
.9:1 (all four doses of vaccine 3B). Because higher num-
ers of male mice develop clinical signs of poliomyelitis
han female mice, male mice are more susceptible to
oliovirus infection. The response curves of males and
emales, which differ from each other, were nearly iden-
ical for both mouse lines (data not shown).
To determine if receptor dosage plays a role in the
ifferential poliovirus susceptibility of male and female
ice, pvr abundances in CNS tissues of male and female
GM-PRG-3 mice were compared by Western blot anal-
sis. As illustrated in Fig. 4, the level of pvr in the brain,
rain stem, and spinal cord tissues was similar in TGM-
RG-3 males and females. Similar pvr abundances were
lso observed in TGM-PRG-1 male and female CNS
issues (data not shown). Abundance of pvr, therefore, is
ot responsible for the increased poliovirus sensitivity of
ale mice.
DISCUSSION
The use of TgPVR mice has enabled the identification
f different parameters that contribute to the disease
tate following poliovirus infection, including the strain of
oliovirus, the dose of virus, and the gender of the
ouse. The relative neurovirulence of the strain of po-
iovirus, as defined by the monkey neurovirulence test for
PV vaccines, is a major contributor to disease severity
n TgPVR mice. This shows that TgPVR mice respond to
arious polioviruses similarly to humans and monkeys.
ccumulated data from these six poliovirus mouse chal-
enge tests clearly demonstrate repeatability of poliovi-
us strain and dose differentiation by these two mouse
ines. The strong dose dependence exhibited by TgPVR
ice, however, is not observed in monkeys (Furesz and
ontreras, 1993).
These results testify that TgPVR mice are able to
rchestrate the stages of a poliovirus infection beyond
irus binding and cell entry when poliovirus is delivered
o the CNS. Host factors, necessary for translation and
eplication of the poliovirus genome (Barton et al., 1995;
amarnik and Andino, 1996), must be present in mouse
NS cells infected by poliovirus. Further support for the
resence of these host factors in the mouse CNS is the
imilarity of the neuropathology in poliovirus-infected
gPVR mice, monkeys, and humans (Brownell and Tom-
inson, 1984; Ren et al., 1990; Deatly et al., unpublished
esults).
Perhaps more interesting, and less well understood, is
he strong contribution of gender to poliovirus neuroviru-
ence in these transgenic mice. As illustrated, male
ransgenic mice are more likely to develop poliomyelitis
han female mice and a higher proportion of males than
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225POLIOMYELITIS IN PV-SENSITIVE MICEemales die after developing paralysis. Epidemiology
tudies in humans suggest the same phenomenon; i.e.,
uman males are more susceptible than females to en-
eroviruses, especially polioviruses (with a male:female
atio between 1.5:1 and 2.5:1, respectively). These ratios
ndicate that 60–70% of all enteroviral disease occurs in
ales (Moore, 1982; Morens and Pallansch, 1995). While
he biological significance of this observation is not
nown in humans, Gelfand (1962) correlates these ob-
ervations with extended periods of virus excretion,
igher excretion titer, and higher infection rate in other-
ise healthy male versus female subjects. The overall
atios of poliomyelitis in mice over the four doses is 1.9:1
males to females), a ratio similar to that in humans.
hereas it is not yet known if the excretion times are
onger and titers are higher in male versus female TgPVR
ice, it is known that the incidence of disease is higher
n males.
The relative abundance of pvr was compared in CNS
issues of male and female mice to gain insight into the
ifferential susceptibility based on gender. However, the
bundance of the poliovirus receptor is similar in the
ale and female CNS tissues in both transgenic mouse
ines. Perhaps a difference in expression of another gene
n male versus female neurons (Amrein and Axel, 1997),
otential differences in immune responses between
ales and females, and/or hormonal differences affect
usceptibility to poliovirus infections (Shanahan, 1997).
thers have speculated that the higher proportion of
isease in adult human males versus females is attrib-
table to muscle trauma or increased muscular activity
Moore, 1982; Morens et al., 1991) or injury-provoked
oliomyelitis (Gromeier and Wimmer, 1998). While the
iological significance of this phenomenon is intriguing,
he cause of increased poliovirus susceptibility in males
FIG. 4. Western blot hybridization of pvr in TgPVR mouse CNS tissues.
lanes 4 and 5), and spinal cord (lanes 6 and 7) homogenates from ma
s nontransgenic mouse brain (lane 8), were subjected to PAGE using
ane 9 contains Novex prestained molecular weight markers (not detec
nd pvr and actin were detected using monoclonal antibodies 5H5 (1:1
or signal detection. Exposure time was 30 min.ay be difficult to determine. dInterestingly, even though the poliovirus receptor is
hreefold more abundant in the brains of TGM-PRG-3
han in those of TGM-PRG-1 mice (Deatly et al., 1998),
here is no statistically significant difference in poliovirus
usceptibility between these mouse lines. This result,
irst observed in TgPVR mice inoculated IC with wild-type
II (Leon) poliovirus into mice from both mouse lines
Deatly et al., 1998), is confirmed here with less neuro-
irulent polioviruses inoculated into the spinal cord. IS,
ather than IC inoculation, was used for the experiments
n this report to ensure consistency of delivery of polio-
irus to the same target site. This is possible in the spinal
ord because the transverse processes highlight spe-
ific vertebrae. IS inoculation data demonstrate that
GM-PRG-1 and TGM-PRG-3 mice are equally suscepti-
le to poliovirus infection; both capable of distinguishing
ifferences in neurovirulence for different poliovirus
trains/vaccines; and equivalent in the frequency and
agnitude of clinical signs produced in response to
irulent virus challenge. In contrast, two poliovirus-sen-
itive transgenic mouse lines produced in the ICR ge-
etic background, TgPVR1 and TgPVR21 (a ratio of 10:3,
espectively), differ in poliovirus susceptibility which ap-
ears to correlate with poliovirus receptor and gene
osage (Koike et al., 1994). The reason(s) for the differ-
nce in these results is not yet understood.
Increased receptor dosage does, however, appear to
ffect the time to onset of disease in TGM-PRG-1 and
GM-PRG-3 mice. Failure time is significantly shorter in
GM-PRG-3 mice relative to TGM-PRG-1 mice.
It is clear, from these and other studies, that the
eceptor plays a major role in the initial interaction of the
irus with CNS tissues, since nontransgenic mice do not
evelop poliomyelitis (Ren et al., 1990; Deatly et al.,
npublished results). Future experiments are planned to
micrograms of membrane fractions of brain (lanes 2 and 3), brainstem
s 2, 4, and 6) and female (lanes 3, 5, and 7) TGM-PRG-3 mice, as well
rylamide in the presence of DTT. Lane 1 contains 125 ng of actin and
photography). The separated proteins were transferred to PDVF filters
actin A4700 (Sigma; 1:50), respectively. Chemiluminesence was usedFifteen
le (lane
8% ac
ted by
0) andetermine if the poliovirus receptor is functional in facil-
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226 DEATLY ET AL.tating an infection if the virus is administered orally.
hese studies should be key to elucidating the pathway
or poliovirus infections affecting CNS tissues via the
atural route of infection.
Since poliovirus-infected TgPVR mice develop clinical
igns of poliovirus similar to those of humans and they
ifferentiate the neurovirulence of various strains ac-
ording to dose, TgPVR mouse is an appropriate animal
odel for the safety testing of oral poliovirus vaccines.
esults from these experiments and others (Dragunsky
t al., 1996) also suggest the possibility of using clinical
igns of paralysis and mortality as the assay endpoint for
his regulatory test, rather than neuropathological eval-
ation of CNS tissues.
MATERIALS AND METHODS
iruses
Vaccine 3B and WHO/III polioviruses were obtained from
r. David J. Wood (National Institute of Biological Safety and
tandards, United Kingdom). The WHO/III (a Sabin original
fter two passages-SO 1 2) poliovirus (an attenuated vac-
ine based upon the monkey neurovirulence test; Dragun-
ky et al., 1996) is used as the reference virus for this assay.
ll oral poliovirus vaccines must be subjected to the mon-
ey neurovirulence test to demonstrate consistency and
afety of vaccine manufacture. Vaccine 3B poliovirus failed
he monkey neurovirulence test.
Mutation analysis by PCR restriction enzyme cleavage
MAPREC) assays (Chumakov et al., 1991) were per-
ormed on these polioviruses to determine the percent-
ge of cytosine (C) at nucleotide 472. The change from a
racil (U) to a C at nucleotide 472 in type III OPV vaccines
orrelates with an increase in histologic lesion scores in
onkeys inoculated in the spinal cord (Chumakov et al.,
991). Vaccines which fail the monkey neurovirulence
est generally have greater than 1% 472-C (Dragunsky et
l., 1996).
aintenance of mouse lines
TGM-PRG-1 and TGM-PRG-3 are new mouse lines
ransgenic with the human poliovirus receptor gene and
re recently characterized (Deatly et al., 1998). TGM-
RG-1, TGM-PRG-3, and nontransgenic mice are main-
ained and bred under viral antigen-free conditions at
harles River Laboratories. Barrier-derived homozygous
GM-PRG-1 and TGM-PRG-3 male mice were bred to
57BL6/J (nontransgenic) females to produce offspring
emizygous for the transgene. Maintenance and trans-
ort of these transgenic mouse lines were performed in
ompliance with the guidelines recommended by the
HO in a memorandum titled “Maintenance and Distri-
ution of Transgenic Mice Susceptible to Human Vi-
uses” (1993). All animal housing conditions and experi-
ents were approved by Wyeth-Lederle Vaccine and
ediatric’s Animal Care and Use Committee. mntraspinal inoculation of mice
Four- to six-week-old TGM-PRG-1 and TGM-PRG-3
ice were inoculated IS with the type III poliovirus vac-
ines 3B and WHO/III. The mice were anesthetized with
0 mg/mL ketamine and 0.4 mg/mL xylazine adminis-
ered intraperitoneally (ip) at a rate of 300–500 mL/g of
ody weight. When the anesthetized mice lost pedal
eflexes, the lumbar regions in the spinal cords were
xposed by cutting the skin aseptically, and 5 mL of virus
noculum was delivered to the gray matter of the spinal
ord between the 13th thoracic and 1st lumbar vertebrae.
customized 33-gauge needle (15°) and Exmire mi-
rosyringe obtained from the Ito Corporation (Japan)
ere used to administer virus. After inoculation, the in-
ision was glued with Vetbond (3M Company). The mice
ere observed for 14 days for development of clinical
igns of poliomyelitis (Dragunsky et al., 1996).
tatistical analysis
Paralysis and mortality 50% endpoints were calculated
y the Spearman–Karber method. To compare neuroviru-
ent effects of the vaccine 3B and WHO/III reference
irus, clinical scores and failure times were tested by
ontingency table and proportional hazard analyses, re-
pectively. Calculations were performed with the JMP
tatistical program for the Macintosh computer to esti-
ate likelihood ratio x2 values, factor effects, and prob-
bilities (Lehman and Sall, 1994). For generating contin-
ency tables, infectivity dose, sex, and virus type were
sed as classifying variables to specify categories in the
nalysis (Goodman, 1978). In each experiment, the hy-
othesis that the clinical score is independent of vaccine
as tested. Failure time was analyzed as right-censored
ata in proportional hazard tests (Kalbfleisch and Pren-
ice, 1980). Logistic regression was used to compare
ose–responses of the mouse lines.
etection of pvr in membrane fractions of transgenic
NS tissues
TGM-PRG-1, TGM-PRG-3, and nontransgenic mice were
irst anesthetized and perfused with PBS (GIBCO-BRL) to
emove the blood. The brain, brain stem, and spinal cords
ere homogenized separately in homogenizing buffer
0.025 M sucrose, 1 mM EDTA, pH 8, 20 mM Tris–HCl, pH
.2, and protease inhibitor cocktail tablets (Boehringer
annheim)] with a polytron homogenizer (Brinkmann In-
truments) to prepare 10% emulsions (w/v). The homoge-
ates were centrifuged at 400g for 5 min (4°C), then the
upernatants were centrifuged at 14,000g, for 30 min at
°C. 250 mL of homogenizing buffer, plus 1% NP40, were
dded to the pellets of the second spin (membrane frac-
ion), incubated on ice for 1 h, then centrifuged at 14,000g,
or 30 min (4°C). Protein concentrations of the solublizedembrane fractions (i.e., supernatants) were determined
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227POLIOMYELITIS IN PV-SENSITIVE MICEsing a micro-BCA assay (Pierce). Fifteen micrograms of
otal protein per sample were heated at 85°C in sample
uffer containing 25 mM DTT for 5 min then loaded onto 8%
crylamide gels (Novex). Following electrophoresis, the
roteins were transferred to PVDF filters (Novex); the filters
ere blocked overnight in the presence of 1% blocking
eagent (Boehringer Mannheim) plus 5% sheep serum
Sigma). Filters with the transferred proteins from the three
ouse lines were incubated for 3–4 h with monoclonal
ntibodies to pvr (1:10 dilution hybridoma cell culture su-
ernatant of 5H5; Koike et al., 1994a) plus actin (1:50; Sigma
4700) in blocking reagent with gentle shaking at room
emperature. After being washed twice with TBS, contain-
ng 0.1% Tween 20, followed by 0.5% blocking reagent, for 10
in each at room temperature, the filters were incubated
ith 71.4 mU/mL sheep anti-mouse/anti-rabbit IgG horse-
adish peroxidase (Boehringer Mannheim) for 30 min at
oom temperature. The filters were washed four times with
BS, containing 0.1% Tween 20, for 15 min each at room
emperature. The abundances of pvr and actin were visu-
lized using a Boehringer Mannheim Chemiluminescence
estern blotting kit (Cat. No. 1520709) and a 30-min expo-
ure to Bio-Max ML film (Kodak). The actin and pvr protein
ands were quantitated using a GS-700 densitometer (Bio-
ad).
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